We describe the cloning and characterization of a novel fusion protein (termed L19-mIL12), consisting of murine interleukin-12 in single-chain format, sequentially fused to the L19 antibody in tandem diabody format. The fusion protein bound avidly to the cognate antigen (the alternatively-spliced EDB domain of fibronectin), retained the activity of the parental cytokine and was able to selectively localize to murine tumors in vivo, as shown by quantitative biodistribution analysis. L19-mIL12 exhibited a potent anti-tumor activity in immunocompetent mice bearing CT26 carcinomas and WEHI-164 sarcomas, which could be boosted by combination with check-point blockade, leading to durable cancer eradication.
NOVELTY AND IMPACT STATEMENT
In this study, we describe the generation of a novel fusion protein consisting of murine interleukin-12 fused to the L19 antibody (specific to the EDB domain of fibronectin). L19-mIL12
revealed favorable tumor to organ ratios 24h after intravenous administration and it was able to cure 60% of CT26 tumor-bearing mice. From a clinical perspective, the rapid clearance from circulation should ease the administration to patients as infusions could be stopped upon onset of side-effects.
INTRODUCTION
Immune check-point inhibitors (such as antibodies targeting PD-1, PD-L1 or CTLA-4) are revolutionizing the treatment of patients with various types of malignancies 1-3 . These biopharmaceuticals can be considered as "foundational drugs", to which other therapeutic regimens may be added, in order to achieve optimal anti-cancer activity 4, 5 . In particular, inhibition of the PD-1/PD-L1 axis may help reverse an exhausted phenotype in CD8 + T cells, which have previously encountered tumor-associated antigens [6] [7] [8] . As a consequence, these therapeutic strategies are likely to be more effective, when a substantial number of tumorspecific lymphocytes are present within the solid tumor mass 9 .
Cytokines are a class of immunomodulatory proteins, which have been considered as biopharmaceuticals for cancer therapy 10, 11 . In particular, certain pro-inflammatory cytokines (such as interleukin-2, -12 and -15) could potentially be used to boost the activity of T cells and NK cells within the neoplastic mass. However, most cytokine products cause side effects at low doses (sometimes even at 1µg/Kg in patients), thus preventing dose escalation to therapeutically active regimens 12 . The fusion of cytokines to antibodies, capable of selective localization to the tumor mass, has been proposed as a means to increase the therapeutic index of these biopharmaceuticals [13] [14] [15] . Some antibody-cytokine fusions are currently being investigated in the clinic for the treatment of different types of malignancies [16] [17] [18] [19] [20] [21] [22] [23] [24] .
Interleukin-12 (IL12) is a heterodimeric cytokine consisting of the p40 and p35 subunits, linked by a disulfide bond 25, 26 . The protein is predominantly produced by Antigen Presenting Cells (APCs) upon recognition of "danger signals" such as pathogen associated molecular patterns (PAMPs) 25, 27 . IL-12 can bind to its cognate receptor, composed of IL12Rߚ1 and has also been shown to (i) increase the proliferation of NK, CD4 + and CD8 + T cells, (ii) increase antigen processing and presentation by APCs, (iii) augment ADCC against cancer cells, (iv) inhibit Treg activity, promoting their polarization towards a T H 1 phenotype, (v) en-hance IgG production and (vi) alter expression patterns of endothelial adhesion molecules such as VCAM-1 27 .
For the last two decades, various groups, including our own, have worked on the engineering of antibody-IL12 fusions, since the heterodimeric nature of IL12 poses various opportunities for protein engineering, leading to formats with different pharmacokinetic and pharmacodynamic properties [28] [29] [30] . Two antibody-IL12 fusions have recently entered clinical trials for treatment of patients with cancer: BC1-IL12 16 and NHS-IL12 (NCT01417546) 31 .
Both fusion proteins are based on intact immunoglobulin structures. However, antibody fragments may be preferable for the generation of IL12 fusion proteins, in order to achieve a more rapid clearance from circulation and better tumor:organ ratios 32 .
Here, we describe a novel fusion protein (termed L19-mIL12), consisting of a single-chain murine interleukin-12, sequentially fused to the L19 antibody in tandem diabody format. L19 specifically recognizes the alternatively-spliced EDB domain of fibronectin, a highly selective tumor-associated antigen. Over the last 20 years, several publications (based on the L19 antibody or similar phage-derived antibodies) have confirmed EDB as a pan-tumoral antigen, which is undetectable in most normal tissues, exception made for certain structures of the female reproductive system 33 . L19 recognizes both murine and human EDB with identical affinity, since the domain sequence is completely conserved between the two species 34 . However, since the human isoform of IL12 does not cross react with the cognate murine receptor, preclinical studies in mice were performed using the murine IL12 as therapeutic payload 35 .
The L19-mIL12 product, which retained full activity in terms of both antigen binding and cytokine activity, was potently active against CT26 carcinomas and cured all mice when combined with CTLA-4 or PD-1 blockade. The fusion protein was also potently active also against LLC but, in this case, complete tumor eradications could not be achieved, not even in combination with immune check-point inhibition. While in both models L19-mIL12 mediated an increased density of intratumoral CD8 + T cells and NK cells, Treg density was dramatically increased only in LLC tumors. Staining of CD8 + T cells with tetramer reagents in the CT26 model revealed a striking difference between tumor-infiltrating lymphocytes and their counterparts in tumor-draining lymph nodes. The results of our study suggest that a fully human L19-IL12 fusion protein may be considered for clinical development activities.
RPMI-1640 (Thermo Fisher) supplemented with antibiotic-antimycotic (Thermo Fisher; 15240-062) and 10% Fetal Bovine Serum (Gibco; 10270-106). 100ߤL of the cell suspension was incubated for 5 days at 37Ԩ and 5% CO 2 with a serial dilution of the IL12 derivatives.
Cultured supernatants were analysed by a sandwich enzyme-linked immunosorbent assay (ELISA) using 5 ߤ g/mL of the monoclonal anti-mouse IFN-ߛ antibody (eBioscience) for capture and 1 ߤ g/mL of the polyclonal biotinylated anti-mouse IFN-ߛ antibody (PeproTech) for detection.
Cytokine analysis in tumor extracts and plasma
For a quantitative analysis of cytokines in tumors extracts and in plasma, CT26 and LLC bearing mice were euthanized 24h after 3 intravenous injections, every third day, of PBS or 12ߤg of L19-mIL12. BALB/c mice were immediately exsanguinated and the blood was left to clot for 1h at room temperature in Microtainer tubes containing lithium heparin (BD Microtainer Tube). Plasma was collected after centrifugation, aliquoted and frozen at -80°C until cytokine assays were performed.
Excised Lewis Lung and CT26 carcinomas were suspended in 2mL of Tris-HCl buffer (50mM, pH 7.4) containing NaCl (0.6M), Triton X-100 (0.2%), BSA (0.5%) and freshly dissolved protease inhibitors (1mM benzamidine, 0.1mM benzethonium chloride and 0.1mM phenylmethylsulfonyl fluoride). Tumors were homogenized with QIAGEN Tissue Lyser (4 x 1', 30 Hz) using a 5mm stainless steel bead (Qiagen, Hombrechtikon, Switzerland) and sonicated for 20s. Supernatants were collected after centrifugation, aliquoted and frozen at -80°C until cytokine assays were performed.
Cytokine levels were eventually measured using a multiplexed particle-based flow cytometric assay 38 . The kits Luminex Screening assay (LXSAMS-5 and LXSAMS-6) and Luminex Perfomance Assay (LTGM100) were purchased from Bio-Techne (Zug, Switzerland). The procedure closely followed the manufacturer's instructions and the analysis was conducted using a conventional flow cytometer (Guava EasyCyte 8HT, Millipore, Zug, Switzerland) at the Cytolab facility (Ostring 48, CH-8105 Regensdorf).
Immunofluorescence studies
The expression of EDB (+)-fibronectin in CT26, LLC, MC38, F9 and WEHI-164 tumors was studied on ice-cold acetone-fixed 8-10ߤm cryostat sections stained with FITC labeled IgG(L19) (FITC_F7250 Sigma) (final concentration 2ߤg/mL) and detected with a Rabbit anti-FITC (Bio-Rad; 4510-7804) and Goat anti-Rabbit AlexaFluor488 (Invitrogen; A1108). For vascular staining, goat anti-CD31 (R&D System; AF3628) and anti-goat AlexaFluor594 (Invitrogen; A11058) antibodies were used.
For ex vivo immunofluorescence analysis, mice were injected according to the therapy schedule and euthanized 24h after the last injection. Tumors were excised and embedded in cryoembedding medium (ThermoScientific) and the corresponding cryostat tissue sections (8-10ߤm thickness) were stained using the following primary antibodies: goat anti-CD31
(R&D System; AF3628), rabbit anti-caspase-3 (Sigma; C8487), rabbit anti-Foxp3 (Invitrogen; 7000914), rabbit anti-Asialo GM1 (Wako; 986-10001), rabbit anti-CD4 (Sino Biological; 50134-R001), rabbit anti-CD8 (Sino Biological; 50389-R208). Primary antibodies were detected with Donkey anti-rabbit AlexaFluor488 (Invitrogen; A11008) and Donkey anti-goat AlexaFluor594 (Invitrogen; A21209). Slides were mounted with fluorescent mounting medium (Dako Agilent) and analyzed with wide field Axioskop2 mot plus microscope (Zeiss) using the AxioVision software (4.7.2 Release, Zeiss). Quantification of the infiltrate analysis, 
In vivo quantitative biodistribution analysis
The tumor homing ability of L19-mIL12 was assessed by in vivo quantitative biodistribution studies, according to a previously described procedure 39 BioXCell) . One saline group (n=5) and one treatment group (n=4-5) were included in both models as controls. The injection of the depleting antibodies was started 2 days prior to therapy initiation and performed every third day for 4 times (except made for the anti-Asialo GM1 that was given 3 times). Animals were euthanized when tumors reached 1500mm 3 or weight loss exceeded 15%.
Flow cytometric analysis of CD4 + T cells, CD8 + T cells and CD8 AH1-specific T cells in tumor draining lymph nodes and in the tumor
CT26 tumor-bearing mice were sacrificed after 1 and 3 injections of PBS or 12ߤg of L19-mIL12.
Excised tumors were cut in small fragments, passed through a 40ߤm nylon cell-strainer (EASYstrainer, greiner bio-one), and digested for 2h at 37Ԩ at 110rpm in RPMI-1640 (Thermo Fisher, with L-glutamine) containing antibiotic-antimycotic solution, 1mg/mL collagenase II (Thermo Fisher) and 0.1mg/mL DNase I (Roche). Cell suspensions were passed through a 70ߤm nylon cell-strainer (EASYstrainer, greiner bio-one), repeatedly washed and immediately used for flow cytometry analysis.
Excised tumor draining lymph nodes (dLN) were minced in PBS, treated with Red-Blood Cell Lysis Buffer (BioLegend) and passed through a 40ߤm nylon cell-strainer (EASYstrainer, greiner bio-one). The cell suspensions were then repeatedly washed and immediately used for flow cytometry analysis. Tree Star).
Histopathological evaluation of BALB/c mice
Healthy BALB/c were euthanized 24h after the third administration of saline or 12µg L19-mIL12. The same treatment schedule of the tumor therapies depicted in Figure 3 was used. A full necropsy was conducted in each mouse, main organs were removed and fixed in 4% neutral-buffered formalin (Formafix, Hittnau, Switzerland) for 48 h. After fixation tissues were trimmed, dehydrated in graded alcohol and routinely paraffin wax embedded. Consecutive sections (3-5μm thick) were prepared, mounted on glass slides and routinely stained with haematoxylin and eosin (HE).
RESULTS
Cloning and characterization of the L19-mIL12 fusion protein Figure 1A the impact on other cytokines (e.g., IL2, IL4, IL17A) was less pronounced [ Figure 1G , H].
Injections of L19-mIL12 in BALB/c mice at doses up to 12ߤg were well tolerated, as revealed by a detailed histopathological analysis [Supplementary Figure 2] .
The staining characteristics of the L19 antibody against various types of murine tumors is depicted in Figure 2A . While certain tumors (e.g. CT26, LLC) exhibited a predominantly stromal pattern of staining, F9 teratocarcinomas showed a more perivascular expression pattern. Similar findings have been reported for human tumors 40 . When injected intravenously into immunocompetent mice bearing F9 teratocarcinomas, a radioiodinated preparation of L19-mIL12 revealed a preferential uptake in the solid tumor mass 24 hours after bolus injection, with 7 percent injected dose per gram (%ID/g) of tumor, compared to less than 1% ID/g in blood [ Figure 2B ].
Therapy experiments
In a first therapy study conducted in BALB/c mice bearing CT26 tumors, L19-mIL12 exhibited a potent tumor-growth inhibition activity at a dose of 8.75µg. The product was very well tolerated, as evidenced by no loss of body weight, and more efficacious than KSF-mIL12 (a fusion protein of irrelevant specificity, directed against hen egg lysozyme and used as a negative control) [ Figure 3A ].
The preliminary study provided a motivation to increase the dose of L19-mIL12 to 12µg and to test the product in combination with mouse-specific immune check-point inhibitors. In this setting, 3/5 mice could be cured by the L19-mIL12 monotherapy, while 4/5 and 5/5 complete responses could be achieved in combination with CTLA-4 or PD-1 blockade respectively
[ Figure 3B ]. The immune check-point inhibitors only showed only minimal single agent activity [ Supplementary Figure 5 ] 41, 42 . Surprisingly, the combination with the anti-PD-L1 antibody was not well tolerated and mice had to be prematurely sacrificed, due to the loss of body weight [ Figure 3B ]. In order to minimize PD-L1-related toxicity, mice with WEHI-164 sarcoma were given only two injections of anti-PD-L1 antibody in all study groups [ Figure   3C ]. L19-mIL12 was potently active in inhibiting tumor growth also in this model, leading to durable complete responses in all combination groups. In the monotherapy group, only one mouse enjoyed a durable complete response with L19-mIL12, whereas tumors progressed upon treatment with immune checkpoint inhibitors alone [ Figure 3C ].
A similar investigation was conducted in C57BL/6 mice, bearing subcutaneous LLC tumors.
In this case, a tumor growth inhibition activity of L19-mIL12 could be observed, but mice could not be cured, not even in combination with immune check-point inhibitors [ Figure   3D ].
In order to gain more insights into the different performance of L19-mIL12 in CT26 and LLC tumors, we performed immunohistochemical and cytokine analysis on tumors, collected 24h after the last injection (i.e., 8 and 6 days after the first injection in the CT26 and LLC models, respectively). The most striking effect of L19-mIL12 in CT26 was the marked elevation of NK cells and CD8 + T cells within the tumor mass. By contrast, the density of Tregs was low in all treatment groups [ Figure 4A ]. The density of NK cells and CD8 + T cells was also increased in LLC tumors. However, in this model, a substantial increase in Tregs was observed for all mice treated with L19-mIL12 (alone or in combination) [ Figure 4B ]. Protein extracts from tumors were analyzed with a multiplex cytokine analysis. We observed elevated levels of IFNെߛ and MIG in the treatment group of both CT26 and LLC models [ Supplementary   Figure 3 ].
We performed a FACS characterization of leukocytes isolated from the CT26 tumor mass or from tumor-draining lymph nodes of BALB/c mice (24h after the first or third injection).
Specifically, we studied features of CD4 + and CD8 + T cells, as well as a subset of these lymphocytes which are specific to AH1 (a retroviral antigen which drives anti-tumor responses in BALB/c mice) 43-45 [ Figure 5 ]. The proportion of CD8 + T cells specific to AH1 was low (approximately 1%) in tumor-draining lymph nodes but increased over time both for saline and L19-mIL12 treatment groups. By contrast, 41.3% and 54.7% of the intratumoral CD8 + T cells were specific to AH1 after 1 and 3 injections of L19-mIL12, respectively [ Figure 5A ]. This observation suggests an active role of AH1-specific lymphocytes within the tumor mass, whose number is slightly increased by the targeted delivery of IL12 compared to the saline treatment. In tumor draining lymph nodes both CD4 + and CD8 + T lymphocytes had a naïve phenotype (i.e., CD62L + CD44 -), while the CD8 + AH1-specific subset showed effector memory features (i.e., CD62L -CD44 + ) suggesting a specific anticancer role for this latter population.
[ Figure 5B ]. These findings were paralleled by the observation of an exhausted phenotype (in terms of PD-1 expression) for CD8 + AH1-specific T cells, with a higher proportion of proliferating cells (Ki67 positive) in relation to the total CD8 + T lymphocytes [ Figure 5C ]. Analysis of the tumor bed revealed a predominantly effector memory phenotype for both CD4 + and CD8 + T cells (i.e., CD62L -CD44 + ), whose frequency was not affected by the treatment [ Figure 5D ]. Moreover, intratumoral infiltrating T cells expressed high levels of immunoregulatory receptors, such as PD-1 and Tim-3, whose densities were not substantially modified by the administration of targeted IL12 [ Figure 5E ]. An analysis of vital cells within the tumor mass only revealed a significant increase in tumor cell mortality after the third injection of L19-mIL12 [ Figure 5F ], in keeping with the progressive decrease of the tumor size [ Figure 3 ]. The immunohistochemical findings of Figure 4A on Tregs were confirmed by FACS analysis, with no substantial change in the proportion of CD4 + Foxp3 + T cells [ Figure 5G ].
In order to functionally confirm the contribution of various lymphocyte populations to the anti-tumor activity, we performed therapy studies in both CT26 and LLC models, following a depletion of NK cells and T cell subsets. CD8 + T cells and NK cells were crucially important for anti-cancer immunity in both tumor types. However, the role of CD4 + T cells in the LLC model was dispensable and a depletion of Tregs, mediated by an anti-CD25 antibody, did not potentiate the action of L19-mIL12 [ Figure 6 ].
DISCUSSION
We have described the production of a novel fusion protein (L19-mIL12), which selectively homes to the tumor extracellular matrix, achieving high local concentrations of murine interleukin-12 at the tumor site. The fusion protein was potently active against murine CT26 and WEHI-164 tumors in the immunocompetent setting, and could further be potentiated by combination with CTLA-4 or PD-1 blockade. Anti-tumor activity was also observed against In mice, L19-mIL12 was very well tolerated at a dose of 12µg, which is equivalent to the human dose of 2mg, under consideration of the body surface scaling factor 16, 17 . The lack of toxicity was corroborated by the absence of weight loss [ Figure 3B and C] and by the histopathological analysis of organs by necropsy [ Supplementary Figure 2 ]. Cancer cures for CT26 carcinomas correlated with a local increase of CD8 + T cells and NK cells in tumors, following administration of the antibody-IL12 fusion protein. As expected, the majority of T cells in the neoplastic lesions were different from those in secondary lymphoid organs, with a predominance of AH1-specific CD8 + T cells 43-45 [ Figure 5 ]. Despite the fact that these cells displayed an exhausted phenotype in terms of PD-1 expression, they still contributed to the therapy outcome, as indicated by the lymphocyte depletion studies. High levels of PD-1 and Tim-3 were found also on AH1-specific CD8 + T cells in the spleen of BALB/c mice that had successfully rejected a tumor rechallenge after a first cancer cure [ Supplementary Figure 8 ].
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